참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 3-Bromopyridine | HCID 12286 | — |
| 반응물 | (R)-1-Boc-3-methylpiperazine | HCID 2756811 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 촉매 | 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl | HCID 16217985 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | tert-butyl (3R)-3-methyl-4-pyridin-3-ylpiperazine-1-carboxylate | HCID 89555981 | 102.97% |
반응 단계
_Repeat of reaction EN05798-78_ Diacetoxypalladium (0.112 g, 0.50 mmol) and dicyclohexyl(2',6'-diisopropoxybiphenyl-2-yl)phosphine (0.466 g, 1.00 mmol) were dissolved in toluene (15 mL) at ambient temperature under nitrogen. The mixture was degassed and purged with nitrogen several times and heated to 50°C for 20 mins. In a separate vessel, were mixed 3-bromopyridine (0.789 g, 4.99 mmol), sodium 2-methylpropan-2-olate (0.720 g, 7.49 mmol), (R)-tert-butyl 3-methylpiperazine-1-carboxylate (1g, 4.99 mmol) and toluene (10 mL). The mixture was degassed and purged with nitrogen several times. The catalyst mixture was added to the reaction vessel and the resulting mixture was degassed and purged with nitrogen, and heated at 100 °C under nitrogen overnight. The reaction mixture was filtered through celite, washing with EtOAc/MeOH. The filtrate was concentrated and the residue purified by flash silica chromatography, elution gradient 20 to 100% EtOAc in heptane. Pure fractions were evaporated to dryness to afford (R)-tert-butyl 3-methyl-4-(pyridin-3-yl)piperazine-1-carboxylate (1.426 g, 103 %) as a pale orange gum. [Rf ~ 0.1 in 1:1 EtOAc/hept] Note: Trace Ruphos contaminating product
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-b33a6a5e9f314a52b92d41be195f749c |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|